| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's …
Over the last 12 months, insiders at Iovance Biotherapeutics, Inc. have bought $0 and sold $0 worth of Iovance Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Iovance Biotherapeutics, Inc. have bought $35.94M and sold $503,000 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $55,200 was made by Kirby Daniel Gordon (Chief Commercial Officer) on 2025‑06‑05.
| 2025-06-05 | Kirby Daniel Gordon | Chief Commercial Officer | 30,000 0.0092% | $1.84 | $55,200 | +39.44% | ||
| 2025-05-23 | Puri Raj K. | Chief Regulatory Officer | 5,600 0.0016% | $1.74 | $9,743 | +38.48% | ||
| 2025-05-14 | Vogt Frederick G | Interim CEO & General Counsel | 25,000 0.0074% | $1.69 | $42,250 | +42.69% | ||
| 2024-11-12 | Sale | Maynard Ryan D | director | 50,000 0.0169% | $10.06 | $503,000 | -70.23% | |
| 2024-02-20 | Rothbaum Wayne P. | director | 5M 1.4985% | $9.15 | $45.75M | -21.28% | ||
| 2024-02-20 | MCPEAK MERRILL A | director | 250,000 0.0749% | $9.15 | $2.29M | -21.28% | ||
| 2024-02-20 | Dukes Iain D. | director | 32,000 0.0096% | $9.15 | $292,800 | -21.28% | ||
| 2023-09-18 | MCPEAK MERRILL A | director | 10,000 0.0038% | $5.56 | $55,600 | +44.27% | ||
| 2023-09-15 | Rothbaum Wayne P. | director | 5M 2.0294% | $5.30 | $26.5M | +60.53% | ||
| 2022-12-21 | MCPEAK MERRILL A | director | 10,000 0.0062% | $6.15 | $61,500 | +5.62% | ||
| 2022-12-02 | Rothbaum Wayne P. | director | 10M 5.7676% | $6.50 | $65M | -6.58% | ||
| 2022-11-29 | MCPEAK MERRILL A | director | 10,000 0.0062% | $6.31 | $63,100 | +4.40% | ||
| 2022-11-28 | MCPEAK MERRILL A | director | 10,000 0.0063% | $6.18 | $61,800 | +7.73% | ||
| 2022-11-28 | Vogt Frederick G | Interim CEO & General Counsel | 1,000 0.0006% | $5.98 | $5,980 | +7.73% | ||
| 2022-11-23 | Dukes Iain D. | director | 10,000 0.006% | $6.10 | $61,000 | +3.22% | ||
| 2022-06-01 | Vogt Frederick G | Interim CEO & General Counsel | 1,000 0.0006% | $6.44 | $6,440 | +22.88% | ||
| 2022-05-31 | Rothbaum Wayne P. | 500,000 0.3188% | $6.77 | $3.38M | +15.11% | |||
| 2022-05-31 | WEISER MICHAEL | 2,187 0.0014% | $6.79 | $14,850 | +15.11% | |||
| 2022-05-31 | MCPEAK MERRILL A | 10,000 0.0064% | $6.84 | $68,400 | +15.11% | |||
| 2022-05-31 | Maynard Ryan D | 7,500 0.0048% | $6.75 | $50,588 | +15.11% |
| Rothbaum Wayne P. | director | 28067333 6.1963% | $247.83M | 6 | 0 | +35.41% |
| BRISTOL INVESTMENT FUND LTD | 10 percent owner | 10023628 2.2129% | $88.51M | 1 | 0 | |
| Singh Manish | President & CEO | 1938500 0.428% | $17.12M | 1 | 0 | +84% |
| Schroeder Martin | director | 1000000 0.2208% | $8.83M | 1 | 0 | |
| Vogt Frederick G | Interim CEO & General Counsel | 374646 0.0827% | $3.31M | 3 | 0 | +24.44% |
| MCPEAK MERRILL A | director | 320150 0.0707% | $2.83M | 9 | 0 | +28.01% |
| Puri Raj K. | Chief Regulatory Officer | 206852 0.0457% | $1.83M | 1 | 0 | +38.48% |
| WEISER MICHAEL | 104819 0.0231% | $925,551.77 | 1 | 0 | +15.11% | |
| Dukes Iain D. | director | 54000 0.0119% | $476,820.00 | 3 | 0 | +32.19% |
| Kirby Daniel Gordon | Chief Commercial Officer | 30000 0.0066% | $264,900.00 | 1 | 0 | +39.44% |
| Maynard Ryan D | director | 7500 0.0017% | $66,225.00 | 1 | 1 | +15.11% |
$11,583,737 | 45 | 49.75% | $4.66B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$151,136,640 | 31 | -1.41% | $3.95B | |
$5,066,938 | 27 | 26.38% | $3.7B |
| Increased Positions | 156 | +59.54% | 62M | +29.04% |
| Decreased Positions | 107 | -40.84% | 13M | -6.26% |
| New Positions | 53 | New | 4M | New |
| Sold Out Positions | 40 | Sold Out | 4M | Sold Out |
| Total Postitions | 311 | +18.7% | 262M | +22.78% |
| Mhr Fund Management Llc | $72,997.00 | 7.3% | 28.97M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $65,410.00 | 6.54% | 25.96M | +3M | +11.7% | 2025-09-30 |
| Vanguard Group Inc | $60,629.00 | 6.06% | 24.06M | -1M | -4.06% | 2025-09-30 |
| State Street Corp | $33,541.00 | 3.35% | 13.31M | +3M | +34.57% | 2025-09-30 |
| Invenomic Capital Management Lp | $26,565.00 | 2.66% | 10.54M | +2M | +27.09% | 2025-09-30 |
| Long Focus Capital Management, Llc | $22,974.00 | 2.3% | 9.12M | -3M | -22.87% | 2025-09-30 |
| Palo Alto Investors Lp | $19,198.00 | 1.92% | 7.62M | +4M | +122.15% | 2025-09-30 |
| Geode Capital Management, Llc | $17,308.00 | 1.73% | 6.87M | +679,245 | +10.97% | 2025-09-30 |
| Goldman Sachs Group Inc | $16,570.00 | 1.66% | 6.58M | +2M | +38.44% | 2025-09-30 |
| Bank Of America Corp /De/ | $15,824.00 | 1.58% | 6.28M | +2M | +55.83% | 2025-09-30 |